A case of yellow fever vaccine-associated disease

New Zealand Medical Journal

Volumn 125, Issue 1349, 2012, Pages

  Isenman, Heather ^a   Burns, Andrew ^a  

^a Hastings Memorial Hospital   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFUSION FLUID; INOTROPIC AGENT; YELLOW FEVER VACCINE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; CLINICAL EXAMINATION; DIAPHORESIS; DIARRHEA; EPISTAXIS; FEVER; HEART ATRIUM FIBRILLATION; HEMOFILTRATION; HEPATITIS; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; LABORATORY TEST; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPHADENOPATHY; MEDIASTINUM MASS; MULTIPLE ORGAN FAILURE; NEUROLOGIC EXAMINATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RESPIRATORY FAILURE; RESUSCITATION; TACHYCARDIA; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; URINE VOLUME; VACCINATION; YELLOW FEVER FLAVIVIRUS; ACUTE KIDNEY FAILURE; FATALITY; LETTER; YELLOW FEVER;

ACUTE KIDNEY INJURY; AGED; DIARRHEA; EPISTAXIS; FATAL OUTCOME; HUMANS; MALE; RESPIRATORY DISTRESS SYNDROME, ADULT; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84858047818     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-6.
2. Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011; 11: 622-32.
3. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, doubleblind clinical trial. Am J Trop Med Hyg. 2002;66:533-41.
4. www.cdc.gov/travel (accessed on 06/06/2011) archived at http://www.webcitation.org/61hyhJ1AK
5. CDC 2010 Yellow Fever Vaccine, Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR 59(RR07);1-27.
6. Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D- 204 yellow fever vaccination: a report of four cases. Lancet. 2001 14;358:98-104.
7. Khromava AY, Eidex RB, Weld LH, et al; Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.Vaccine. 2005 9;23:3256-63.
8. Barwick R; Eidex for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet. 2004 11-17;364:936.
9. Thomas RE, Lorenzetti DL, Spragins W, et al. VActive and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine. 2011 Jun 20;29:4544-55.